Iterum Therapeutics (ITRM) Competitors $0.03 0.00 (0.00%) As of 05/21/2026 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM vs. TCRT, RNAZ, ACXP, FBLG, and APVOShould you buy Iterum Therapeutics stock or one of its competitors? MarketBeat compares Iterum Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Iterum Therapeutics include Alaunos Therapeutics (TCRT), TransCode Therapeutics (RNAZ), Acurx Pharmaceuticals (ACXP), FibroBiologics (FBLG), and Aptevo Therapeutics (APVO). These companies are all part of the "pharmaceutical products" industry. ITRM vs. TCRTITRM vs. RNAZITRM vs. ACXPITRM vs. FBLGITRM vs. APVOHow does Iterum Therapeutics compare to Alaunos Therapeutics?Alaunos Therapeutics (NASDAQ:TCRT) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Does the media refer more to TCRT or ITRM? In the previous week, Alaunos Therapeutics had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for Alaunos Therapeutics and 0 mentions for Iterum Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.54 beat Iterum Therapeutics' score of 0.00 indicating that Alaunos Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Alaunos Therapeutics Positive Iterum Therapeutics Neutral Is TCRT or ITRM more profitable? Iterum Therapeutics' return on equity of 0.00% beat Alaunos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alaunos TherapeuticsN/A -165.94% -123.50% Iterum Therapeutics N/A N/A -65.54% Do institutionals and insiders hold more shares of TCRT or ITRM? 27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate TCRT or ITRM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Which has better earnings & valuation, TCRT or ITRM? Alaunos Therapeutics has higher earnings, but lower revenue than Iterum Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlaunos TherapeuticsN/AN/A-$4.18M-$2.13N/AIterum Therapeutics$390K4.10-$24.77M-$0.75N/A Which has more volatility & risk, TCRT or ITRM? Alaunos Therapeutics has a beta of -1.13, indicating that its share price is 213% less volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the broader market. SummaryIterum Therapeutics beats Alaunos Therapeutics on 7 of the 12 factors compared between the two stocks.How does Iterum Therapeutics compare to TransCode Therapeutics?Iterum Therapeutics (NASDAQ:ITRM) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Which has better earnings and valuation, ITRM or RNAZ? Iterum Therapeutics has higher revenue and earnings than TransCode Therapeutics. TransCode Therapeutics is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum Therapeutics$390K4.10-$24.77M-$0.75N/ATransCode TherapeuticsN/AN/A-$34.66M-$50.33N/A Do institutionals and insiders believe in ITRM or RNAZ? 9.2% of Iterum Therapeutics shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by company insiders. Comparatively, 0.0% of TransCode Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer ITRM or RNAZ? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more volatility and risk, ITRM or RNAZ? Iterum Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Does the media prefer ITRM or RNAZ? In the previous week, TransCode Therapeutics' average media sentiment score of 1.08 beat Iterum Therapeutics' score of 0.00 indicating that TransCode Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Iterum Therapeutics Neutral TransCode Therapeutics Positive Is ITRM or RNAZ more profitable? Iterum Therapeutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -65.54% TransCode Therapeutics N/A -875.35%-50.36% SummaryIterum Therapeutics beats TransCode Therapeutics on 9 of the 11 factors compared between the two stocks.How does Iterum Therapeutics compare to Acurx Pharmaceuticals?Acurx Pharmaceuticals (NASDAQ:ACXP) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends. Which has preferable valuation & earnings, ACXP or ITRM? Acurx Pharmaceuticals has higher earnings, but lower revenue than Iterum Therapeutics. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$7.97M-$4.05N/AIterum Therapeutics$390K4.10-$24.77M-$0.75N/A Does the media favor ACXP or ITRM? In the previous week, Acurx Pharmaceuticals had 2 more articles in the media than Iterum Therapeutics. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 0 mentions for Iterum Therapeutics. Acurx Pharmaceuticals' average media sentiment score of 0.79 beat Iterum Therapeutics' score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Acurx Pharmaceuticals Positive Iterum Therapeutics Neutral Is ACXP or ITRM more profitable? Iterum Therapeutics' return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -153.92% -101.69% Iterum Therapeutics N/A N/A -65.54% Do analysts rate ACXP or ITRM? Acurx Pharmaceuticals presently has a consensus price target of $31.00, indicating a potential upside of 1,473.60%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Iterum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Do insiders and institutionals believe in ACXP or ITRM? 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, ACXP or ITRM? Acurx Pharmaceuticals has a beta of -2.09, meaning that its stock price is 309% less volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, meaning that its stock price is 196% more volatile than the broader market. SummaryAcurx Pharmaceuticals beats Iterum Therapeutics on 8 of the 14 factors compared between the two stocks.How does Iterum Therapeutics compare to FibroBiologics?Iterum Therapeutics (NASDAQ:ITRM) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment. Does the media favor ITRM or FBLG? In the previous week, FibroBiologics had 2 more articles in the media than Iterum Therapeutics. MarketBeat recorded 2 mentions for FibroBiologics and 0 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 0.00 equaled FibroBiologics'average media sentiment score. Company Overall Sentiment Iterum Therapeutics Neutral FibroBiologics Neutral Is ITRM or FBLG more profitable? Iterum Therapeutics' return on equity of 0.00% beat FibroBiologics' return on equity.Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -65.54% FibroBiologics N/A -767.07%-195.56% Which has higher valuation & earnings, ITRM or FBLG? FibroBiologics has lower revenue, but higher earnings than Iterum Therapeutics. FibroBiologics is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum Therapeutics$390K4.10-$24.77M-$0.75N/AFibroBiologicsN/AN/A-$18.65M-$6.93N/A Do analysts prefer ITRM or FBLG? FibroBiologics has a consensus price target of $74.00, suggesting a potential upside of 6,947.62%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts clearly believe FibroBiologics is more favorable than Iterum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders have more ownership in ITRM or FBLG? 9.2% of Iterum Therapeutics shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by insiders. Comparatively, 9.3% of FibroBiologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, ITRM or FBLG? Iterum Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. SummaryIterum Therapeutics beats FibroBiologics on 7 of the 13 factors compared between the two stocks.How does Iterum Therapeutics compare to Aptevo Therapeutics?Aptevo Therapeutics (NASDAQ:APVO) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation. Which has better earnings & valuation, APVO or ITRM? Iterum Therapeutics has higher revenue and earnings than Aptevo Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptevo TherapeuticsN/AN/A-$25.97M-$197.60N/AIterum Therapeutics$390K4.10-$24.77M-$0.75N/A Which has more volatility & risk, APVO or ITRM? Aptevo Therapeutics has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the broader market. Do institutionals and insiders believe in APVO or ITRM? 8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 0.1% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 2.0% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to APVO or ITRM? In the previous week, Aptevo Therapeutics had 2 more articles in the media than Iterum Therapeutics. MarketBeat recorded 2 mentions for Aptevo Therapeutics and 0 mentions for Iterum Therapeutics. Aptevo Therapeutics' average media sentiment score of 0.33 beat Iterum Therapeutics' score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aptevo Therapeutics Neutral Iterum Therapeutics Neutral Is APVO or ITRM more profitable? Iterum Therapeutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aptevo TherapeuticsN/A -198.50% -117.06% Iterum Therapeutics N/A N/A -65.54% Do analysts recommend APVO or ITRM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 SummaryIterum Therapeutics beats Aptevo Therapeutics on 8 of the 13 factors compared between the two stocks. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition ExportMetricIterum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.60M$3.04B$6.39B$12.31BDividend YieldN/A1.97%2.76%5.30%P/E Ratio-0.0417.7921.1425.65Price / Sales4.10336.21553.1286.87Price / CashN/A57.6544.5756.72Price / Book-0.205.8610.357.12Net Income-$24.77M$74.99M$3.56B$335.28M7 Day PerformanceN/A-0.11%4.91%2.66%1 Month PerformanceN/A-5.14%1.51%1.39%1 Year PerformanceN/A34.05%36.04%35.43% Iterum Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics0.0835 of 5 stars$0.03flatN/AN/A$1.60M$390KN/A10TCRTAlaunos Therapeutics1.1561 of 5 stars$2.63flatN/A-6.7%$6.31MN/AN/A40Earnings ReportGap UpRNAZTransCode Therapeutics0.5818 of 5 stars$6.72-4.0%N/A-22.7%$6.18MN/AN/A9Positive NewsEarnings ReportACXPAcurx Pharmaceuticals2.4467 of 5 stars$2.05-6.0%$31.00+1,412.2%-76.5%$5.85MN/AN/A3Gap UpFBLGFibroBiologics2.9266 of 5 stars$1.10+11.1%$74.00+6,627.3%-94.3%$5.73MN/AN/A10Gap Up Related Companies and Tools Related Companies Alaunos Therapeutics Alternatives TransCode Therapeutics Alternatives Acurx Pharmaceuticals Alternatives FibroBiologics Alternatives Aptevo Therapeutics Alternatives Psyence Biomedical Alternatives Cardio Diagnostics Alternatives Redhill Biopharma Alternatives Aptorum Group Alternatives Cuprina Holdings (Cayman) Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITRM) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredThe Most Important Tech Company in America?One private company holds over $26 billion in government contracts tied to AI warfare and defense systems - an...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
